Key takeaways
- MOTS-c is a peptide; NAD+ is a coenzyme, not a peptide.
- MOTS-c studies include cell and animal research; the human research cited here measured naturally occurring MOTS-c, not an administered peptide.
- FDA’s compounding list (updated 14 May 2026) places NAD, the coenzyme, in Category 1, “Bulk Drug Substances Under Evaluation”.
- WADA’s 2026 and 2027 Lists name MOTS-c in S4.4.1, prohibited at all times. Neither names the coenzyme NAD+; the List’s classes include substances it does not name, and anti-doping organisations decide how they apply.
01MOTS-c vs NAD+ in one table
Status checks and evidence summarized as of 21 November 2026. Each status is what the named document or database shows on that date; none is a legal conclusion of ours.
| Question | MOTS-c | NAD+ |
|---|---|---|
| What it is | A 16-amino-acid peptide encoded by a short open reading frame in mitochondrial 12S rRNA. | Nicotinamide adenine dinucleotide, a coenzyme; not a peptide. |
| Evidence tier | Cell (T4) and animal (T3) studies, not evidence of an effect in people; human studies measured natural levels (T2). | Human trials are small (T1), as graded on its guide; work in rodents is further along (T3), a 2021 review says. |
| Human data | A 2021 study measured naturally occurring MOTS-c in 10 sedentary men; it did not give MOTS-c. We found no published study that gave MOTS-c to people (PubMed and ClinicalTrials.gov, 21 Nov 2026). | A 2026 analysis that pooled four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, and a rise in a kidney marker with NAD+. Studies of precursors are not studies of NAD+ itself. |
| United States | FDA staff wrote that neither form is “a component of an FDA-approved drug” and recommended against adding MOTS-c to the 503A bulks list; HHS records that its advisory committee voted in favour of both forms. HHS’s October 2026 draft policy, which “is not binding”, names MOTS-c. | FDA’s 503A list (updated 14 May 2026) places NAD in Category 1, “Bulk Drug Substances Under Evaluation”. Drugs@FDA lists no product containing nadide or nicotinamide adenine dinucleotide (openFDA, 21 Nov 2026). |
| United Kingdom | The emc medicines database returned no results for MOTS-c (21 Nov 2026); it is not the full UK register. | The emc database returned no results for nadide or nicotinamide adenine dinucleotide (21 Nov 2026); it is not the full UK register. |
| Australia | The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” MOTS-c has no entry by name in the Poisons Standard October 2026; we draw no scheduling conclusion of our own. | The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines (safety alert, last updated 3 Feb 2026). The Poisons Standard October 2026 does not name it; we draw no scheduling conclusion of our own. |
| Sport | Named in WADA class S4.4.1, metabolic modulators, and prohibited at all times under both the 2026 and 2027 Lists. | Not named on the 2026 or 2027 List. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply. |
02How are the molecules different?
If you searched “mots c vs nad”, start with identity. MOTS-c is a peptide sequence; NAD+ is a coenzyme. They are not two names for the same molecule, and a finding about one does not transfer to the other.
MOTS-c
FDA describes MOTS-c as a 16-amino-acid peptide encoded within mitochondrial 12S rRNA.
NAD+
Nicotinamide adenine dinucleotide is a different molecular class. It is not a peptide sequence.
Separate evidence
A result about one molecule cannot establish a result about the other.
For MOTS-c, FDA’s briefing describes the peptide and its mitochondrial origin. For NAD+, the FDA compounding list uses the name “Nicotinamide Adenine Dinucleotide (NAD).” The names in those documents identify distinct substances; they do not make the substances interchangeable.
03What human research is described here?
The human evidence shown for MOTS-c is about naturally occurring levels, not administration of the peptide.
Reynolds and colleagues’ 2021 study measured naturally occurring MOTS-c in muscle and blood in 10 sedentary men, with a mean age of 24.5 years. This is T2 evidence about measured levels, not a trial of administered MOTS-c.
MOTS-c research also includes cell experiments and animal models. Those are T4 and T3 evidence tiers, respectively, and do not establish an effect in people.
NAD+ has its own small trials (T1), graded on its guide. Before comparing a human study, identify whether it measured NAD+ itself or a precursor such as nicotinamide riboside.
For the MOTS-c research record and its limits, see the MOTS-c research guide. The studies summarized here do not provide a head-to-head comparison of MOTS-c and NAD+.
04What do the status checks show?
The table reports what the named documents say on the dates given, not a legal verdict for a reader or a particular material.
United States. FDA’s 503A list (updated 14 May 2026) places NAD in Category 1, which it labels “Bulk Drug Substances Under Evaluation”. For MOTS-c, FDA staff wrote that neither form is “a component of an FDA-approved drug” and recommended against adding it to the 503A bulks list; HHS records that its advisory committee voted in favour of both forms, and HHS’s October 2026 draft policy, which “is not binding”, names MOTS-c. These are different statements about different regulatory questions.
United Kingdom and Australia. The UK emc database returned no results for MOTS-c, nadide or nicotinamide adenine dinucleotide (21 November 2026), and the Poisons Standard October 2026 names neither molecule. The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines. We draw no scheduling or legal conclusion of our own.
Sport. WADA’s 2026 and 2027 Lists name MOTS-c in S4.4.1. Neither names NAD+, NAD or nadide; the List’s classes include substances it does not name, and anti-doping organisations decide how they apply.
For MOTS-c, FDA’s briefing also distinguishes MOTS-c free base from MOTS-c acetate as different bulk drug substances. To assess what a particular report identifies, read how to read a COA; a purity percentage alone does not distinguish MOTS-c from a different molecule.
05What we don’t know
- How MOTS-c and NAD+ compare in people. The cited MOTS-c human study measured natural levels; it did not compare the two molecules.
- Whether the small NAD+ trials say anything beyond the people and measures they studied.
- How anti-doping organisations would apply the List’s classes to NAD+, which the List does not name.
- What is in any particular vial. A report must identify the lot and provide a distinct identity result.
This is a plain-English summary of public documents and studies, checked on 21 November 2026. It is not legal or medical advice.